Key result
Low-dose transdermal scopolamine increases vagal cardiac inhibition and lowers BP while improving standing HRV.
Why the study?
The effects of low-dose transdermal scopolamine on autonomic cardiovascular regulation and its modulation by posture in healthy young subjects were not fully understood.
Does low-dose transdermal scopolamine alter autonomic cardiovascular regulation in healthy young volunteers?
RCT (n=10)
Double-blind
Randomized
Does low-dose transdermal scopolamine alter autonomic cardiovascular regulation in healthy young volunteers?
Low-dose transdermal scopolamine increases vagal cardiac inhibition and decreases blood pressure in healthy young subjects, with posture-dependent effects on heart rate variability.
We studied how posture influences the effects of transdermal scopolamine on autonomic cardiovascular regulation in a randomized, double-blind, placebo-controlled crossover study of 10 healthy young volunteers. We recorded the electrocardiogram and auscultatory sphygmomanometric and continuous non-invasive finger arterial pressure (Finapres device) to obtain signals for the beat-by-beat R-R interval and systolic, mean and diastolic pressures. R-R interval and arterial pressure variabilities were characterized by power spectral analysis. Scopolamine increased the mean R-R intervals and reduced arterial pressure in both the supine and the standing positions, but did not affect blood pressure variability. Scopolamine increased the total variability of R-R interval and its mid- (0.07-0.15 Hz) and high- (0.15-0.40 Hz) frequency band power in the standing position during controlled breathing at 0.25 Hz. In the supine position, scopolamine did not affect R-R interval variability. In the deep breathing test, scopolamine increased the maximal expiratory-inspiratory R-R interval ratio. This study showed that low-dose scopolamine increases vagal cardiac inhibition in both supine and standing positions in healthy volunteers. However, scopolamine increases heart rate variability only in the standing position during partial vagal withdrawal. The study also demonstrates that transdermal scopolamine decreases blood pressure in healthy young subjects.
No takes yet. Share an insight, caveat, or question.
Vesalainen et al. (1997) conducted an RCT in Healthy (n=10). Transdermal scopolamine vs. Placebo was evaluated on Autonomic cardiovascular regulation (R-R interval and arterial pressure). Low-dose transdermal scopolamine increased vagal cardiac inhibition and decreased blood pressure in healthy young volunteers, while increasing heart rate variability only in the standing position.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: